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This work is

THE ROLE OF NF-KB ACTIVATION IN BREAST CARCINOMA AND
GLIOBLASTOMA CELL LINES
Kelly T. Murphy, M.S.
Western Michigan University, 2000

The nuclear factor-KB (NF-KB)/Rel family of inducible dimeric transcription
factors regulates numerous genes associated with the immune, mitogenic, and
apoptotic responses.

Investigations were made into the role of NF-KB in breast

carcinoma (MCF-7, T47D, MDA-MB-231) and glioblastoma (U87MG, U373MG,
Ul 18MG) cell lines. NF-KB binding to DNA was quantified using both gel mobility
shift assays and transient transfections of a vector containing a luciferase gene under
the control of 4 tandem copies of the NF-KB binding sequence. To determine the
correlation between NF-KB activation, cellular proliferation, and foci formation, the
tumor cells were cultured and analyzed in the presence of the NF-KB inhibitory
compounds, prostaglandin A 1 (PGA 1) and acetylsalicylic acid (ASA). In addition,
clones of dominant negative mutants which inhibit NF-KB activation were introduced
into these tumor cell lines. One dominant negative mutant is a natural biological
inhibitor of NF-KB, IKBa, modified so that it can no longer be phosphorylated and
degraded. The other dominant negative mutant expressed a truncated form of p65, a
monomer of the NF-KB complex.

Breast carcinomas and glioblastomas showed

elevated NF-KB activation when compared to normal breast epithelial cells. The
tumor cells tested displayed reduced proliferation rates when subjected to NF-KB
inhibition.

Although, foci formation was reduced under the same inhibitory

conditions this response was probably a direct result of decreased proliferation not
cellular transformation.

The investigations presented here demonstrate the

involvement of NF-KB activation with proliferation of these cancer cell lines.
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INTRODUCTION
Epidemiology
Over the last 150 years medical advances have reduced the mortality from
infectious disease and greatly increased the life expectancy of individuals. As a result
other diseases such as cancer have become a major cause of mortality in developed
nations (Cairns, 1988) and cancer research has become the most funded issue in
applied biology (Devesa et al., 1999). There are more than 40 specific categories of
cancer based on the location and phenotype of the tumor cells with 90% of all cancers
originating in epithelial tissue (Devesa et al., 1999). The majority of male mortality
occurs from 4 primary sites of cancer including lung, prostate, colon, and pancreas
(Cairns, 1988). Among females, 60 percent of the mortality occurs from lung, breast,
colon, ovary, and pancreas (Cairns, 1988). In both genders, incidences of breast and
brain cancer increase proportionally with additional genetic pressures from our
environment.
Breast Cancer
In the United States, 200,000 women and 1,600 men are diagnosed each year
with invasive breast cancer and nearly 2,000,000 deaths occurred during 1970-94
(Devesa et al., 1999). Recent advances in detection and screening have reduced the
number of deaths in half to 43,000 annually. Women with a family history of
1

2
developing the disease are at greatest risk but only a small fraction of the breast
cancer cases are attributed to inheritable genotypes (Davidson and Moses, 1998).
Most cases are due to genetic alterations in epithelial tissue forming the ductile and
tubular networks of the breast. Women, who were late in age at first birth and
menopause, early in age for menarche, or go through hormone replacement therapy
have significant increases in risk associated with developing breast cancer (Davidson
and Moses, 1998).

These facts helped establish that ovarian hormones such as

estrogen, progesterone, and insulin-like growth factor play a central role in breast
cancer development. Many of the new and effective agents entering the market such
as Tamoxifen (Evista®) and Raloxifene (Nolvadex®) block estrogenic receptors
(ER) from activating DNA transcription. The HER-2/neu proto-oncogene has also
become an important target against breast cancer. The HER-2/neu gene encodes a
tyrosine kinase receptor that closely resembles the epidermal growth factor receptor
(Rubin and Farbel, 1997). The receptor functions primarily as a heterodimer involved
with differentiation and cell division. Therapeutic antibodies, vaccines, and
chemotherapeutic agents have been developed against both HER/neu and ER. Other
receptors including transforming growth factor (TGF) a and �' platelet-derived
growth factor (PDGF) a and �' fibroblast growth factor and retinoic acid (RAR) have
been shown to be responsible for the development of breast carcinomas (Davidson
and Moses, 1998, Ginsburg and Vonderhaar, 1991, Fan et al., 1999).

Genetic

mutations resulting in up regulation of proto-oncogenes (c-myc, Ha-ras, PTEN,
BRCA-1, BRCA-2) and down regulation of tumor suppressor genes (p53, Rb) have
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also been shown to injtiate breast cancer (Davidson and Moses, 1998, Ginsburg and
Vonderhaar, 1991, Fan et al., 1999, Rubin and Farber, 1997).
Brain and Glial Cancer
The cases of brain or nervous system cancer are fewer in occurrence than
breast cancer with approximately 10,000 deaths annuaJly. From 1970-94 there were
246,222 deaths reported from brain cancer (Devesa et al., 1999) with a bimodal
distribution with respect to age. Young children with genetic predispositions and
elderly adults have much higher incidences of occurrence than middle aged
individuals (Devesa et al., 1999). Most cancers of the brain and nervous system
originate from glial cells that function to support and protect the central nervous
system (CNS) and its components (Xiang, 1995) and the collective terms used for
glial cell tumors are glioblastomas or gliomas. Astrocytomas, the most common type
of glioblastoma, are derived from astrocytes, the star-shaped glial cells, that attach
neurons to their respective blood vessels and create the blood-brain barrier (Xiang,
1995). Glioblastomas are not as well understood as breast carcinomas. As a result,
therapeutic targets remain to be identified and treatment options are limited to surgery
or traditional high dose chemotherapy. Current research is focused on over-activation
in the nuclear signaling pathways associated with nerve growth factor (NGF),
epidermal growth factor (EGF), PDGF, pleiotrophin (PTN), and other neurotrophins
(Couldwell et al., 1991, Hung et al., 2000, Nister et al., 1991). Several types of
mutations within the EGF receptor gene were identified in multiple glioblastomas
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(Frederick et al., 2000).

Granulins, a relatively new class of growth regulators

resembling EGF proteins, have been shown to be associated with glioblastoma
proliferation in vitro (Liau et al., 2000).

Recent investigations have also

demonstrated that increased activity within the regulatory pathways associated with
Akt and Bcl-2 plays a role in glioblastoma proliferation and progression (Frankel et
al., 1999, Zundel et al., 2000).
Platelet-derived Growth Factor Signaling in Breast Carcinomas and Glioblastomas
Production of growth factors by breast carcinomas and glioblastomas is of
central importance because the growth factors are implicated in mediating autocrine
or paracrine stimulation of tumor growth (Rubin and Farber, 1997). Seymour and
Bezwoda (1993) reported that breast cancer patients often have elevated PDGF levels
in plasma.

Many of the cell lines established from breast carcinomas and

glioblastomas have been shown to express PDGF and their receptors (Romashkova
and Makarov, 1999, Bronzert et al., 1987, Rozengurt et al., 1985). PDGF is one of
the major mitogens found in the serum of higher mammals and has been shown to
stimulate the growth and proliferation of connective tissue cells (Ross and Vogel,
1978). Over-expression of PDGF in several tissue types results in mitogenesis which
leads to focus or tumor formation (Claesson-Welsh, 1996). PDGF and its secondary
signaling molecules can act as agents for the malignant transformation in epithelial
tissue (Claesson-Welsh, 1996). Other reports demonstrated that the T47D breast
carcinoma cells had increased proliferation rates in response to exogenous PDGF
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(Ginsburg and Vonderhaar, 1991). StructuraJiy, PDGF is a dimer of some
combination of chains A (17k) and B (14k) linked by disulfide bonds. Its a and �
receptors are transmembrane tyrosine kinases that dimerize and autophosphorylate
after PDGF binding (Claesson-Welsh, 1996). The a receptor binds a11 three isoforms
of PDGF with high affinity whereas the� receptor binds AB and BB dimers. Recent
investigations have led to the assumption that a and � receptors initiate different
signals into the cell, however both receptors are potent activators of the Ph kinase,
PKC, mitogen-activated protein kinase pathways (Claesson-Welsh, 1996). These
signal transduction pathways are associated with many transcription factors including
nuclear factor-KB (NF-KB) (Marumo et al., 1997, Yokote et al., 1996, Romashkova
and Makarov, 1999). Nuclear signaling of PDGF has been shown to activate NF-KB
(Romashkova and Makarov, 1999). As a result, NF-KB could potentially serve as an
important component in transformation and proliferation of breast carcinomas and
glioblastomas responsive to PDGF.
NF-KB
NF-KB activation occurs through a phosphorylation cascade from several cell
surface receptors that are mediated by cytokines and growth factors (Baeuerle, 1991).
NF-KB is an important regulator of transcription for genes needed for cell growth and
differentiation in many cell types. NF-KB has been identified as an inhibitor of
apoptosis and a regulator of cellular transformation (Bauerle and Baltimore, 1996,
Beg and Baltimore, 1996, Wang et al., 1996). Breast carcinoma and glioblastoma
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formation occurs because the tumor cells have lost their ability to regulate their
growth and division making NF-KB an ideal target for research studies within these
tumor cells.

Normal human cells will usually arrest development and then

differentiate in the first phase (G) of the cell cycle but cancerous cells rapidly
proceed through G 1 and advance into the DNA synthesis (S) phase of the cell cycle
(Baldwin, 1991). Inhibition of NF-KB has been shown to significantly reduce G 1 -to-S
phase transitions in fibroblast cells through transcriptional regulation of cyclin D 1
(Guttridge et al., 1999).
Recent reports have linked NF-KB activation to carcinogenesis in a variety of
other types of cells (Abdel-Mageed et al., 1998, Bauerle and Baltimore, 1996,
Reuther et al., 1998). Studies have demonstrated that NF-KB activation is required to
promote tumor growth in Hodgkin's lymphoma and induce cellular transformation in
myelogenous leukemias (Bargou et al., 1997, Daley and Baltimore, 1988).
Transformation of normal epithelial and fibroblast cells by Bcr-Abl and oncogenic
Ras is also dependent on NF-KB activation (Chin et al., 1999, Finco et al., 1997,
Grimm and Baeuerle, 1994, Reuther et al., 1998). Inhibition of NF-KB activity has
been shown to reduce the growth of MCF-7 breast carcinomas and friend
erythroleukemia tumor cells (Abel-Mageed et al., 1998, Marini et al., 1990).
Hypothesis
NF-KB is involved in a variety of cellular processes and it is present in a
majority of cell types as an inducible factor that is activated by multiple stimuli

7
including PDGF (Baeuerle, 1991, Olashaw, 1996).

Once activated, NF-KB can

control the transcription of numerous genes including inflammatory cytokines,
chemokines, growth factors, and proteins associated with cell division, apoptosis,
transformation, and viral replication (Baeuerle, 1991, Baeuerle and Baltimore, 1996,
Guttridge et al., 1999, Verma et al., 1995). This study is designed to investigate the
role that NF-KB inhibition could have on the reduction of focus formation and
proliferation in breast carcinomas (T47D, MDA-MB-231, MCF-7) and glioblastomas
(U87MG, U373MG, Ul 18MG) that express forms of PDGF-like proteins and
receptors.

Representative cell lines established from breast carcinomas and

glioblastomas were chosen specificity because they were shown previously to express
PDGF receptors (Bronzert et al., 1987, Rozengurt et al., 1985). I hypothesize that
inhibition of NF-KB will reduce proliferation and focus formation in these tumor cell
lines.
Structure
The Rel/NF-KB family of transcription factors includes five distinct proteins
that share an approximately 300 amino acid domain of high homology necessary for
DNA binding (Baeuerle and Baltimore, 1996). All the proteins in this family can
form homo- or heterodimeric DNA-binding complexes, each with differences in their
DNA-binding specificity (Baeuerle, 1991). Three proteins, p65 (RelA), RelB and c
Rel, have both DNA-binding and transactivating domains. The other two proteins,
p50 and p52, have only DNA-binding activity (Verma et al., 1995) although, the most
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abundant complex of NF-KB is the heterodimer p65/p50. A consensus NF-KB
recognition sequence has been developed based on the sequences bound by NF-KB
from several genes (Baeuerle and Baltimore,1996). This sequence contains 10 base
pairs with guanines always the first three bases and the last two bases predominantly
cytosines, 5'-GGGAATTTCC-3'.
Inhibition by IKB
A family (a, y, � 8) of inhibitory proteins commonly termed IKB, exerts post
'
translational control on NF-KB activity by their binding to cytoplasmic NF-KB dimers
(Rice and Ernst, 1993). In vitro, IKBa binds to p65, RelB and c-Rel where it prevents
NF-KB nuclear translocation (Verma et al., 1995). Stimulation of the IKB kinases
(IKKa,�) results in phosphorylation of IKB causing it to be released from the NF-KB
heterodimer and causing IKB degradation (Baeuerle, 1991, Rice and Ernst, 1993).
Loss of IKB from the complex allows NF-KB to translocate from the cytoplasm into
the nucleus where it binds to DNA and activates the transcription of genes needed for
growth and proliferation (Figure 1).
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Figure 1.

The Signal Transduction Pathway of NF-KB Activation.

MATERIALS AND METHODS
Cell Lines and Culture
The primary tumor cells were isolated from human patients with malignant
tumors. The breast carcinomas T47D, MDA-MB-231, MCF-7 and glioblastomas
U87MG, U118MG were chosen for this study as previous reports have shown that
they express PDGF-A, B and their receptors a,� (Bronzert et al., 1987, Rozengurt et
al., 1985). The glioblastoma, U373MG, was also used in this study but mRNA and
protein analysis revealed it did not express PDGF-B or the � receptor (Nister et al.,
1991). Cell lines (Table 1) were purchased from American Type Culture Collection
(ATCC) (Rockville, MD) and maintained in minimum essential medium (MEM),
with 10% fetal bovine serum (FBS), 1 00U/ml of penicillin-G, IO0µg/ml
streptomycin, and 0.25µg/ml of amphotericin B. The normal breast epithelial cells,
MCF-l0A, were cultured in a 1:1 mixture of Ham's F12 medium and Dulbecco's
Table 1
Phenotypic Characteristics

Ce11 L.me

U87MG
U373MG
U118MG
T47D
MCF-7
MDA-MB-231
MCF-l0A

Moroho1 ogv
brain glioma, astrocytomas
brain, glioma, astrocytomas
brain, glioma, astrocytomas
breast, ductal, carcinoma
breast, ductal, carcinoma
breast, adenocarcinoma
normal breast ductal tissue
10

· .
ongm

Epithelial
Epithelial
Epithelial
Epithelial
Epithelial
Epithelial
Epithelial
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modified Eagle's medium (DMEM) with 2.5mM L-glutamine, 5% horse serum (HS),
lO0U/ml of penicillin-G and streptomycin, 0.25µg/ml of amphotericin B.
Chemical Inhibitors of NF-KB
Rossi et al. (1997) demonstrated that prostaglandin A 1 (PGA 1 ) at 24µM can
inhibit the activation of NF-KB by inhibiting the phosphorylation of IKBa and as a
result decreases the amount of NF-KB in the nucleus. Similar effects have been
reported for acetylsalicylic acid (ASA) at 5mM (Castano et al., 1997, O'Neil, 1998,
Yin et al., 1998).

Knopp and Ghosh (1994) showed that ASA was capable of

inhibiting the phosphorylation of IKK, a molecule responsible for phosphorylating
IKB proteins. PGA 1 from Biomol Research Laboratories (Plymouth Meeting, PA)
and ASA from Sigma (St. Louis, MO) were diluted in 95% ethanol to convenient
working concentrations before addition to medium.
Quantification of NF-KB Transcriptional Activity
Preparation of Plasmid DNA
pNF-KB-Luc reporter vector was purchased from Clontech laboratories (Palo
Alto, CA). Transfections with pNF-KB-Luc into cells allows the measurement of NF
KB binding through luciferase expression. The control vector without the NF-KB
binding sites was produced through enzymatic digestion with the restriction enzymes
Kpn I and Bgl II. pNFKB-Luc, control, and /3-Gal plasmids were produced in shaking
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cultures of E. coli (DH-lOB) grown m LB medium with lO0µg/ml ampicillin.
Plasmids were purified using StrataPrep EF plasmid rnidiprep kit (Stratagene,
LaJolla, CA), diluted in water or TE buffer and stored at -20° C. Plasmid DNA was
quantified on the Beckman DU-7000 (Fullerton, CA) using spectophotometric
analysis at 260 and 280nm.
Transfection
Cells (104 per well) were seeded onto 8 well culture plates and allowed to
grow to approximately 80% confluence.

In lrnL of medium free of serum,

antibiotics, and antimycotics, 2µg of plasmid DNA was mixed with 10µ1 of
transfection reagent (Gene Therapy Systems, San Diego, CA) for each well. After a
45min incubation, the DNA/reagent mixture was applied to the cells that were
washed twice with phosphate buffered saline (PBS) (137mM NaCl, 2.7mM KC],
4.3mM Na2HPO4, 1.4mM KH2PO4, pH 7.4). At 5 and 24 hours post transfection,
fresh medium with 10% serum and the appropriate treatment was added. For
chemical inhibition experiments, prostaglandin A 1 (PGA 1 ) and acetylsalicylic acid
(ASA) were used at 24µ,M and 5mM respectively.

Seventy-two hours after

transfection, cells were washed with PBS buffer and harvested in 200µL of cell
culture

lysis

reagent

(25mM

Tris-phosphate,

2mM

DTT,

2mM

1,2-

diaminocyclohexane-N,N,N,N-tetraacetic acid, 10% glycerol, Triton® X-100, pH
7.8). The lysate was centrifuged at 12,000 x g for lmin to pellet cell debris. The
supematants were then transferred to new tubes and stored at -80° C.
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Luciferase Quantification
Luciferase luminescence was produced usmg LucLite Plus™ substrate
(Packard, Meriden, CT) and quantified on Packard TopCount™ Microplate
scintillation counter. Samples containing lOOµg of lysate protein, quantified by the
bicinchoninic acid assay (BCA kit) (Pierce, Rockford, IL) were prepared in triplicate
following manufacture's protocol. Results were normalized to transfection efficiency
determined by �-galactosidase expression in the tumor and normal cells transiently
transfected with a �-Gal plasmid from Invitrogen (Carlsbad, CA) containing the lacZ
gene construct. �-galactosidase expression was quantified using �-Gal assay kit and
manufacturer's recommendations (Invitrogen).
Proliferation Assay
Cell proliferation assays were performed in 96 well format usmg
manufacturer's recommendations and the Cell Counting kit-8 (Dojindo Molecular
Technologies Inc., Gaithersburg, MD). The kit employs a novel tetrazolium salt that
produces a highly soluble formazan dye upon biochemical reduction in the presence
of an electron carrier. Four hours after cells were incubated with the tetrazolium salt,
quantification of the dye was accomplished through the measurement of absorbance
at 450nm. The cells were initially quantified using a hemocytometer and seeded
approximately 104 cells per well. Twenty-four hours after seeding, medium with 2%
serum and the appropriate treatment was added. Medium with inhibitors, PGA 1 at
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24µ,M and ASA at 5mM, was replaced on the 151, 3 rd , and 5th days of the experiment.
Cell numbers were measured for 6 consecu6ve days. After generating a standard line
for each cell line, absorbencies were then converted to cell number. Proliferation
experiments involving mutants and MCF-lOA were modified to the appropriate
medium with 2% serum and assayed for 8 consecutive days with measurements taken
every second day.
Focus Formation Assay
To evaluate cellular transformation, tumor and normal cell lines were seeded
in 24 well culture plates with an initial cell density of ~20,000/cells per well and
examined for contact inhibition or foci formation. The appropriate treatment was
added 24 hours after seeding. Respective medium with 2% serum was replaced every
second day.

After ten-days, cells were stained with 0.25% crystal violet for

quantification of foci formation.
Construction of pmeIKBa and p65�C Dominant Negative Mutants
Preparation of pmeIKBa and p65�C Clones
The pmelKBa and p65�C, p65 gene constructs were the kind gifts of Drs.
Nancy Rice and Nancy Colburn (National Cancer Institute, Bethesda, MD). All of
these constructs contain the pRc/CMV vector (lnvitrogen). pmeIKBa is a dominant
negative mutant of IKBa while p65�C contains a C-terminal deletion of p65. NF-KB
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inhibition by pmeIKBcx and p65�C dominant negative mutants has been shown
previously (Rice and Ernst, 1993, Guttridge, et al., 1999, Grimm and Baeuerle, 1994).
The plasmids were grown in shaking cultures of E. coli (DH-10B) at 37 ° C with LB
medium containing lO0µg/ml ampicillin. Plasmids were purified using StrataPrep EF
plasmid midiprep kit (Stratagene). The plasmid DNA diluted in water or TE buffer
was quantified through spectophotometric analysis at 260 and 280nm.
Stable Transfections
Stable cell lines expressing the dominant negative mutants and wild type
genes were created for each tumor cell line using transfection recommendations and
reagents from Gene Therapy Systems (San Diego, CA). Cells (104 per well) were
seeded in 8 well plates and transfected at -80% confluence with 5µg per well of
plasmid DNA and 10µ1 reagent (Gene Therapy Systems).

After 24 hours of

transfection, fresh medium with 10% serum was added and then replaced 48 hours
post transfection with fresh medium containing 10% serum and 0418 antibiotic at
400ug/ml or 800ug/m1 for MDA-MB-231 cell line. The stably transfected cells were
maintained permanently in medium containing the 0418 antibiotic. Three individual
clones were isolated from within each stable culture using cloning cylinders and
0.05% trypsin in PBS and 58mM EDTA for removal from the plates. The cells
expressing the dominant negative mutants were assayed for NF-KB transcriptional
activity, proliferation and foci formation as described previously.

Clones stably
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transfected with the empty pRc/CMV vector, p65 wild type and mock transfected
cells were used as controls.
Western Blot Analysis
Western blotting was performed to ensure expression of genes introduced into
the cells. Cells (105) were seeded in 100mm culture plates and grown until they were
80% confluent. The cells were washed twice with PBS and harvested with 500µL of
r.ell lysis buffer (20mM Tris-HCI, 150mM NaCl, lmM EDTA, lmM EGTA, 2.5mM
sodium pyrophosphate, lmM �-Glycerophosphate, lmM Na3VO4, lµg/mJ Leupeptin,
1 % Triton X-100). Total protein concentrations of the lysate was determined using
the BCA assay kit (Pierce, Rockford, IL). Samples with lOµg of lysate protein were
prepared with reducing buffer (570mM Tris-HCI, pH 6.8, 10% glycerol, 5% 2mercaptoethanol,

0.001%

bromophenol

blue).

Sodium

dodecyl

sulfate

polyacrylamide gel electrophoresis (SDS-PAGE) was used to separate the proteins
based on size (Laemmli, 1970). Samples were electrophoresed at 60V for 45min
followed by ll0V for 90min in IX running buffer (250mM Tris-base, 192mM
glycine, and 0.1% SDS).

Proteins were transferred to a PVDF membrane through

electroblotting for 2 hours at 4° C in buffer containing 250mM Tris and 192mM
glycine. The membrane was first blocked overnight at 4° C with 5% I-block
(Amersham Pharmacia Biotech, Piscataway, NJ) diluted in Tris-HCI (20mM), NaCl
(137mM), and 0.1%Tween 20 (TBS-T). Then primary antibody anti-IKB (Upstate
Technologies, Lake Placid, NY) was diluted to 0.5 µg/ml in I-block/TBS-T and also
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°

incubated with the membrane overnight at 4 C.

Anti-rabbit IgG (Amersham

Pharmacia Biotech), conjugated with horseradish peroxidase, was diluted (1 :2000) in
fresh 1-block/TBS-T and incubated with the membrane at room temperature for l
hour.

After washing the membrane 3 times in TBS-T, the antibodies on the

membrane were detected using the ECL Plus® Western Blotting Kit (Amersham
Pharmacia Biotech) and exposed to Kodak X-omat film for 30min.
Fluorescent Electrophoretic Mobility Shift Assay
Preparation of Nuclear Extracts
The tumor and normal breast cells (105 ) were seeded in 100mm culture plates
and harvested at approximately 80% confluence. Cells were washed quickly with
2ml of lx PBS and then removed with 1.5ml of 0.05% trypsin/58mM EDTA left on
for 3-5 minutes. Cells were collected and maintained on ice throughout the protocol
recommended by Promega Inc., (Madison, WA).

The harvested cells were

centrifuged at 2,000 x g for 5min then resuspended and washed in 1ml buffer A
(lOmM HEPES, pH 7.9, l .5mM MgC}z, lOmM KCl, 0.1% NP-40, and 0.5mM DTT).
After recentrifugation, the cells were resuspended with gently pipetting in 80µ1 buffer
A containing 0.1% Triton X-100.

After incubation at 4 °C for 10 minutes, the

homogenate was centrifuged at 2,000 x g for 5min and the nuclear pellet washed in
60µ1 of 20mM HEPES, pH 7.9, 0.42M NaCl, 25% (v/v) glycerol, l .5mM MgC}z, and
0.2mM EDTA. This suspension was incubated on ice for 30 minutes and then
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centrifuged at 16,000 x g for 20 minutes at 4 °C. The resulting supernatant was stored
at -80 °C as nuclear extract.
Reactions With Molecular Beacon
Total protein concentration of the extracts was determined using the BCA
assay (Pierce) and bovine serum albumin (BSA) as a standard. A molecular beacon
containing

a

consensus

NF-KB

recognition

sequence

(Figure

2)

and

carboxyfluorescein (FAM) fluorochrome (Research Genetics Inc, Huntsville, AL)
was used to probe for DNA binding proteins. The assays were performed in 40µL
volumes containing 20µg of nuclear protein and lpmol of molecular beacon and
reverse compliment oligonucleotide (Life Technologies) in the binding buffer (l0mM
HEPES, 50mM KCl, 2.5mM DTT, 0.05% NP-40, 10% glycerol, pH 7.9) for 30
minutes at room temperature. Competition (unlabeled oligo) and specificity (mutated
oligo) experiments were conducted using 50-fold molar excess of the competing
unlabeled oligonucleotides. Super shift assays were conducted using 0.5pmol of
antibody (Upstate Biotechnology) to the p65 subunit of NF-KB. Electrophoresis was
performed on a 7% lX Tris-glycine-polyacrylamide gel and run in 50rnM Tris and
380mM glycine, pH 8.3 buffer. Following electrophoresis at lO0V for 3hrs, the gel
was analyzed by blue-excited fluorescence scanning with the 860 Storm Fluorlmager
(Molecular Dynamics, Sunnyvale, CA).
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KB sequence

Molecular Beacon
Reverse compliment

l

5'-FAM-CATGAACCGGGAATTTCCAACATG-Dabcyl-3'
3'-CCTTGGCCCTTAAAGGTTAA-5'

Unlabeled oligonucleotide

5'-CATGAACCGGGAATTTCCAACATG-3'

Mutated oligonucleotide
Reverse oligonucleotide

5'-CATGAACC�G�AATTTCCAACATG-3'
3'-CCTTGGQCQTTAAAGGTT-5'

Figure 2. Molecular Beacon and Oligonucleotides Used in Gel Shift Assays.
Underlined bases indicate point mutations in oligonucleotides used for
specificity experiments.

RESULTS
Increased Proliferation and Focus Formation of Tumor Cell Lines
Proliferation assays were performed to compare the rate of tumor cells and the
normal epithelial cells. The proliferation rates of the tumor cell lines were greater
than the normal epithelial cells, MCF-lOA (Figure 3). The intrinsic rate of increase
for the 8 day experiment was greatest for the MCF-7 cell line with 9.2 fold increase
per day followed by T47D (8.5), U118MG (7.1), MDA-MB-231 (6.8), U87MG (5.7),
U373MG (4.8), and the rate for the normal cell line, MCF-lOA, was 4.4. To further
characterize the phenotypes of the tumor and normal cells, focus formation assays
were also used to investigate if these cell lines could form foci when cultured over an
extended period of time. Normal cell lines typically have a low occurrence of focus
formation in culture and will arrest mitotic division when there is a single monolayer
of cells covering the culture plate.

In contrast, cancerous cells often form foci or

multiple cell layers because they lack contact inhibition with other cells. The focus
formation assay demonstrated that the tumor cells lacked contact inhibition and
frequently form foci or multiple layers of cells when cultured (Figure 4). The normal
MCF-lOA cells behaved similar to other normal epithelial cell lines forming a single
monolayer in adhesive cultures.
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Figure 3. Elevated Proliferation Rates in Tumor Cell Lines Versus the Normal Breast
Epithelial Cell Line.
Cells were seeded 104 per well in medium containing 2% serum that was
replaced on the 2nd ,4th , and 6th days of the experiment. Measurements were
made every second day for 8 days. Glioblastomas and breast carcinomas are
depicted by closed and open symbols respectively. Open circles illustrate the
normal breast epithelial cell line, MCF-lOA. The data represents the averages
of two independent experiments.
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Blank

MCF-lOA

U87MG
Glioblastoma

T47D
Breast carcinoma

MCF-lOA
Normal breast epithelial cells

Figure 4. Elevated Focus Formation in the Tumor Cell Lines Versus the Normal
Epithelial Cell Line.
Cells were seeded 2xl04 per well in medium containing 2% serum. Medium
was replaced every second day. Cells were stained with 0.25% crystal violet
after the tenth day of the assay. Bottom pictures taken at 40x magnification
on the same cells demonstrate focus formation in representative cell types.
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Elevated NF-KB Transcriptional Activity in the Tumor Cell Lines
Knowing that the tumor cells expressed PDGF like proteins and receptors, I
was interested in quantifying the level of NF-KB transcriptional activition within
these cells. Using transient transfections with either the pNF-KB-Luc plasmid or the
control plasmid without the KB binding sequences, accurate determinations could be
made into the amount of expression initiated by NF-KB. Seventy-two hours after
transfection, the cells were washed and then harvested in lysis buffer. One hundred
micrograms of lysate proteins from the individual samples were mixed with the
Luclite Plus™ substrate (Packard) and luminescence was quantified on a Packard
TopCount™ Microplate scintillation counter.

The data from the transfection

experiments suggests that luciferase expression was elevated in all the tumor cell
lines assayed when compared to the normal breast epithelial cells (Figure 5). The
glioblastoma lines, U87MG and Ul 18MG, had the highest counts per minute (cpm) at
93193 and 98368 respectively. The glioblastoma, U118MG, showed the greastest
level of expression with 14 times more luciferase activity as compared to the MCF
lOA cells. In contrast to the other glioblastomas, the U373MG (16029cpm) did not
have expression levels that were significantly different than the normal MCF-lOA
cell line (6967 cpm). The breast carcinomas MDA-MB-231, T47D, and MCF-7 had
counts of 45524, 34733, 19759 cpm respectively. The MDA-MB-231 line had 5 times
more expression than the normal cells followed by T47D (3) and MCF-7 (2). The
overall expression in glioblastomas was doubled when compared to breast carcinoma
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cell lines. The average NF-KB activation of luciferase expression in glioblastomas
was 9 times higher than MCF-lOA activation. The breast carcinoma cell lines on
average had 5 times more expression than the normal breast epithelial cell line, MCFlOA.
Electrophoretic mobility assays also demonstrated that the tumor cells had a
greater concentration of NF-KB in nuclear extracts (Figure 6).

Samples that

contained nuclear extracts from the tumor cells showed increased binding to the probe
containing KB binding sequence as compared to the normal cell line.

Competition

experiments with 50 molar excess of unlabeled probe showed that binding could be
reduced and was specific. Non-denaturing reactions with the antibody to the p65
subunit demonstrated NF-KB binding could be super shifted in the gel shift assays.
Inhibition NF-KB Transcriptional Activity by PGA 1 and ASA
To accurately assess the inhibition of NF-KB activity by PGA 1 (24µM) and
ASA (5mM), the tumor cell lines were transfected with either the pNF-KB-Luc or
control plasmids in the presence of the chemical inhibitors. Twenty-four hours after
the initiation of transfection, fresh medium with the appropriate inhibitor was added.
Cells were then harvested 72 hours after the initial transfection.

The assays

demonstrated that PGA 1 and ASA were able to reduce expression in all the cell lines
tested (Figure 7). When compared to PGA 1 , ASA was more effective in reducing
expression by an average of 83% in breast carcinomas and 91% in glioblastomas.
The average counts for U87MG, U373MG, Ul 18MG were reduced by ASA from
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Figure 5. Elevated NF-KB Transcriptional Activition in Tumor Cell Lines Versus the
Normal Breast Epithelial Cell Line.
Activation quantified using transient transfections with pNF-KB-Luc vector
(NF +) against control (NF -). The data represents averages (± SD) of samples
assayed in triplicate following manufacture recommendations and protocol.
Luciferase expression quantified through a Packard scinillation counter
(Meriden, CT).
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Figure 6. Gel Shift Assays Demonstrating Increased Binding of NF-KB in Tumor Cell
Lines Versus Normal Epithelial Cells.
Nuclear proteins (20µg) were electrophoresied on 7% acrylamide gel for 3 hrs
at 100V and supershifted with antibody against p65, a subunit of NF-KB
complex. Unlabeled probe at 50pmol was used for competition experiments.
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2125, 550, 2817 cpm to 327, 30, 1080 cpm respectively. ASA also decreased the
activity in the breast carcinomas T47D, MCF-7, MDA-MB-231 from 224, 445, 451,
to 25, 80, 172 cpm respectively. Expression in the presence of PGA 1 was reduced by
an average of 31% for breast carcinomas and 56% for glioblastomas. PGA 1 inhibited
the luciferase activity in U87MG, U373, Ull8MG, T47D, MCF-7, MDA-MB-231
from 2125, 550, 2817, 224, 445, 451 cpm to 941, 284, 918, 112, 331, 361 cpm
respectively.
After demonstrating that PGA 1 and ASA were able to reduce NF-KB induced
-expression, the cell lines were cultured in the presence of these inhibitors to elucidate
the effect on proliferation and foci formation.

The rates of proliferation in the

presence of the inhibitors were determined through the cell counting kit (Dojindo,
Inc). Twenty-four hours after the cells were seeded, the appropriate treatment was
introduced. ASA at 5mM and PGA 1 at 24µM were able to significantly decrease
cellular proliferation in all tumor cell lines treated (Figure 8). PGA 1 produced an
average reduction of 61% in proliferation of breast carcinomas and 60% in
glioblastomas. ASA yielded reduced proliferation rates of 83% in breast carcinomas
and 93% in glioblastomas. The proliferation assays with the inhibitors showed that
division in these cells can be reduced proportional to NF-KB inhibition. To examine
the effect on foci formation, PGA 1 at 6µM, 12µM, 24µM and ASA at 200µM, l mM,
and 5mM were introduced into the medium of tumor cells cultured in 24 well plates.
Foci formation or loss of contact inhibition was reduced when the tumor cell lines
were grown in the presence of PGA 1 or ASA (Figure 9). Tumor cells showed a
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Figure 7. Chemical Inhibition of NF-KB Transcriptional Activity by PGA 1 and ASA.
NF-KB induced expression of luciferase quantified using pNF-KB-Luc vector
(dark bars) against control (light bars). Untreated cells (U) were tested against
cells that were cultured in the presence of PGA 1 (P) at 24µM and ASA at
SmM (A) or mock-transfected (M) cells to demonstrate the inhibition on NF
KB activation. The data represents averages (± SD) of samples assayed in
triplicate.
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Figure 8. Prostaglandin A 1 (PGA 1) and Acetylsalicylic Acid (ASA) Reduce
Proliferation in Tumor Cell Lines.
Cell proliferation assays performed following the protocol as described. Cells
(104 per well) were cultured in MEM with 2% FBS and the appropriate
inhibitor (PGA 1 -24µM or ASA-5mM) for six days. Control cells were
cultured in parallel concentrations of ethanol but without inhibitors. The
results represent averages of two independent experiments.
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Figure 9. Prostaglandin Al (PGA 1 ) and Acetylsalicylic Acid (ASA) Reduce Focus
Formation in Tumor Cell Lines.
The cells (2xl04 per well) were cultured in medium with 2% serum and the
NF-KB inhibitors at increasing concentrations that was replaced every second
day. Control cells were treated with parallel concentrations of ethanol. After
a ten-day period, cells were stained with 0.25% crystal violet. The cells
displayed a dose dependent response to the inhibitors.
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dose dependent response to the inhibitors. The cells still had an increased tendency to
form foci in the presence of the inhibitors relative to normal epithelial cells.
Inhibition of NF-KB Transcriptional Activity by Dominant Negative Mutants
Characteristics of the Cells Transfected With pmelKBa
To verify that NF-KB inhibition reduced proliferation and foci formation,
stable cell lines expressing dominant negative mutants that inhibit NF-KB activity
were established with pmeIKBa and p65LiC. Assays on the cells transfected with
pmelKBa demonstrated that a 60% inhibition of expression occurred in these stably
transfected cells created from each cell line as compared to the cells established with
pRc/CMV (Figure 10). The three clones that were transfected with pmeIKBa and
isolated from the T47D cell line had the greatest inhibition that was 83% lower than
the three clones transfected with pRc/CMV. The clones transfected with pmeIKBa
and established from the U87MG, U3737MG, U118MG, MCF-7, MDA-MB-231 cell
lines had reduced expression by 78%, 47%, 33%, 62%, 45% respectively. Western
blotting demonstrated that all the cells expressing pmelKBa for each tumor line were
over expressing the IKBa insert relative to their wildtype and pRc/CMV cells (Figure
11).

Their proliferation rates were determined through the cell counting kit

(Donjindo, Inc) following the protocol as previously described. The cells were also
counted using a hemocytometer on the 1st and 8th day to qualify the results obtained
with the cell counting kit. Quantification by both methods produced similar rates.
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Figure 10. Reduced Levels of NF-KB Activation in Cells Transfected With pmeIKBa.
Isolated clones expressing the dominant negative mutant pmeIKBa were
compared to the clones transfected with the empty pRc/CMV vector.
Transient transfections, with pNF-KB-luc vector (dark bars) and control (light
bars), were used to examine the amount of NF-KB transcriptional activity in
the cells. The data indicates the averages (± SD) of samples assayed in
triplicate.
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Figure 11. Over-Expression of the IKBa Protein by Cells Transfected With pmeIKBa.
Ten micrograms of protein were electrophoresied on a 10% Tris glycine
polyacrylamide gel. Following electrophoresis proteins were transferred by
electroblotting to a PVDF membrane, and IKB was detected using rabbit anti
IKB and ECLPlus® Western Blotting Kit (Amersham Pharmacia Biotech).
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Table 2
Net Proliferation Rates of the Tumor, pmeIK.Ba, pRc/CMV Cells Quantified
Using a Hemocytometer (A) and Cell Counting Kit (B) After 8 Days Growth
Breast Carcinomas

A

B

Glioblastomas

A

B

T47D wt
6.16
5.49
5.71
7.32
U87MG wt
pRc/CMV #1
pRc/CMV #1
5.83
3.46
6.47
5.86
pRc/CMV #2
_pRc/CMV #2
4.32
4.26
8.30
6.21
pRc/CMV #3
... . . pRc/CMV #3
5.36
5.65
3.88
2.84
pmelKB #1
3.48
3.36
pmelKB #1
3.24
3.33
pmelKB #2
3.11
2.69
· pmelKB #2
2.65
2.12
3.40
pmelKB #3
3.98
2.23
2.54
pmelKB #3
t
6
3.85
.82
5.
3
3
6
.
7
7
7
7
9 .............. ....... ....
............
......................MCF- . wt ..................... ......... .9 ......... · ..........
.......... .........U
MG.. w ........
3.43 .............. ...........3.24 ............
............ pRc/CMv .....#1................ 6.45 ......)..........6.29 .......... . PRc/CMv......#1......
............ pRc/CMv .....#2 ............... : ......J..03 .. .. ... : ..........8.93 .......... . PRc/CMv......#2 .....L.............4.92 .............. ............3·36...... ..
3.22 .............. ............2.19............
............ pRc/CMv .....#3 ............... : . ....J.21
. ........)..........7.64 .......... . PRc/CMv... .#3 .....
1
L
L
.....�:?.] ... ................P.1!1�.1.�.l?.....tt..1. . .. ...........?..:!.� ............. ............?.:.�.?.......... .
....................P..'!1.E3..1�1:3.....!t..�.................... ...... �.:9.�.....
melKB #2
1
3.82 1 3.94
pmelKB #2 1
3.48
2.44
.................... P
···················································••?...............................:..................................
.......................................................; ......................................... .....................................
pmelKB #3
3.00
pmelKB #3 1
2.02
2.34
: 3.61 :
. .8M
. G.. wt ........i..............6.56 .............. ............4.69 .... ... ..
............MDA-MB-231...wt ........... · . .......6.78 ......... . ..........4.31........... ........ U11
pRc/CMV #1 :
pRc/CMV #1
: 5.13 : 4.85
5.77
5.23
#2
#2
52
5
5.61
3
6
.
............... 1 ...........5.67 ............
. .......... ..... PRc/CMv...... .....
...............rRc/CMv ..... ...............1......... . 7 ......
V
1
1. ................L..........?..:.?..9............
P.Rc/CM .�.�......
................P..f3g!.9.�.'!......!t.�............... ?.:.9.1. . . . .
2 ..89 .........1..........3.04 .......... ......... PmelKB....#1... .. ..�............ �.:?.�.............. ...........�:.?..?.............
................. pmelKB...#1....................
...................P..'!1.E3..1�f:3.....!t.?..................
�.:.?..� ......... . ?.:.?..�........... ..........P.meI KB #?. ........l..............�:..!.!.............. ............�:.]..�............
4.72
2.46
pmelKB #3
: 3.45
3.86
pmelKB #3 :

LL.............
L. . . . . .

L.. . .

l. . . . .
lL. . .

. .....

J. . . . .

l.. . . . .?.:.�.�. . . . . . . . .
l.. . . . .
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The assays involving cells transfected with pmeIK.Ba resulted in proliferation rates
that were reduced ~50% from their wild type cells (Table 2). In the tumor cells
measured with the kit, the average proliferation rate of the pmeIK.Ba cells was
reduced 45% from their wild type and pRc/CMV transfected cells (Figure 12). Foci
formation assays using the cells transfected with pmeIK.Ba and pRc/CMV gave
insight into NF-K.B's role on transformation. NF-KB inhibition in the pmeIK.Ba cells
decreased the presence of foci but did not entirely prevent their formation (Figure 13).
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Figure 12. Assays Demonstrating Reduced Proliferation in Cells Transfected With
pmeIKBa.
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Assays were performed following manufacture's recommendations (Dojindo,
Inc). The cells (104 per well) were seeded in 96 well plates and cultured with
the appropriate medium with 2% serum that was replaced every other day.
The results represent (± SD) the averages of four independent experiments.
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Figure 13. Assay Demonstrating Reduced Focus Formation in Cells Transfected With
pmeIKBa.
Cells were seeded 2x104 per well in 24 well plates and cultured with the
appropriate medium containing 2% serum that was replaced every second day.
After ten days the cells were stained with 0.25% crystal violet.
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Characteristics of the Cells Transfected With p65�C
To further test their response to NF-KB inhibition, the tumor cell lines were
stably transfected with p65�C and assayed for activation, proliferation, and focus
formation as described previously. Comparisons between the cells expressing p65
wildtype and p65�C showed that the p65�C transfected cells inhibited NF-KB
induced expression by 70% (Figure 14). The average counts per minute (cpm) for the
three clones transfected with p65�C was reduced in U87MG (70%), U373MG (58%),
U118MG (77%), T47D (65%), MCF-7 (57%), MDA-MB-231 (73%). All the p65�C
transfected cells established, had expression levels lower than both the mock
transfected celJs and cells transfected with p65 wildtype. The U87MG, T47D, MDA
MB-231 clones expressing p65 wildtype had higher expression levels than their
mock-transfected cells similar to results descibed by Baldwin el at. (1995). The
inhibition obtained with the cells transfected with p65�C was 15% greater than the
results obtained with the cells transfected with pmeIKBa. p65�C transfected cells
had decreased proliferation rates and focus formation relative to cells transfected with
p65 wildtype and non-transfected tumor cells (Figure 15, 16). Proliferation in the
p65�C transfected cells was decreased 50% from their mock-transfected cells and
p65 transfected cells (Figure 15, Table 3).

Comparing p65�C and p65 transfected

cells, the greatest decrease in proliferation occurred within the U118MG (75%),
MCF-7 (66%), T47D (50%), U87MG (48%) cell lines. In all the tumor cell lines,
foci formation was significantly decreased in the p65�C transfected cells when

compared to the non-transfected cells and p65 transfected cells (Figure 16).

The

cellular transformation within the p65�C transfected cells was again incomplete and
focus formation was inversely proportional to the proliferation rates.

The non

transfected cells and p65 transfected cells reached full confluence faster and therefore
had a greater opportunity for focus formation.
Table 3
Net Proliferation Rates of the Tumor, p65�C, p65 Cells Quantified
Using a Hemocytometer (A) and Cell Counting Kit (B) After 8 Days Growth

Breast Carcinomas

T47D wt
p65 #1
_p65 #2
__ p65 #3
P65�C #1
P65�C #2
P65�C #3
MCF-7 wt
_p65 #1
p65 #2
_p65 #3
P65�C #1
P65�C #2
P65�C #3
MDA-MB-231 wt
__p65 #1
p65 #2
p65 #3
P65�C #1
P65�C #2
P65�C #3
"'

A

6.53
7.28
6.42
5.79
4.65
5.12
4.08
6.42
8.39
7.34
4.21
4.47
2.89
3.48
5.64
6.33
6.82
5.93
3.61
3.77
4.32

B

8.48
8.26
7.14
10.96
6.41
2.77
3.41
6.29
6.72
4.17
3.64
3.11
2.85
2.79
3.80
4.32
3.03
5.49
2.26
2.45
3.20

Glioblastomas

U87MG wt
__Q65 #1
.,,_Q65 #2
p65 #3
P65�C #1
P65�C #2
P65�C #3
U373MG wt
p65 #1
Q65 #2
p65 #3
P65�C #1
P65�C #2
P65�C #3
U118MG wt
_p65 #1
p65 #2
Q65 #3
P65�C #1
P65�C #2
P65�C #3

A

7.45
8.67
8.38
8.91
5.84
4.13
4.25
8.02
7.86
6.38
6.99
3.36
4.83
3.78
6.42
8.04
7.20
7.81
3.17
3.65
4.53

B

8.52
9.28
9.00
10.23
5.98
3.92
5.61
5.88
6.79
4.64
3.38
2.78
2.37
2.38
6.13
7.36
5.25
6.25
3.99
3.10
2.91
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Figure 14. Reduced Levels of NF-KB Activation in Cells Transfected With p65�C.
Cells expressing the dominant negative mutant p65�C (p65DC) were
compared to cells transfected with the normal p65 insert and the wildtype
cells. Transient transfections, with pNF-KB-luc vector (dark bars) and control
(light bars), were used to examine the NF-KB induced expression of
luciferase. The data indicates averages of samples assayed in triplicate.
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Figure 15. Assays Demonstrating Reduced Proliferation in Cells Transfected With
p65�C.
Assay was performed following the protocol and recommendations from the
Cell Counting kit (Dojindo, Inc). The cells were seeded 104 per well in 96
well plates and cultured with the appropriate medium containing 2% serum
that was replaced every second day. The cells were measured on the 2nd, 4th ,
6 th , and 8 th day. Results are averages of four independent tests (± SD).
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Figure 16. Assay Demonstrating Reduced Focus Formation m Cells Transfected
With p65�C.
Cells were seeded 2x104 per well in 8 well plates and cultured with the
appropriate medium containing 2% serum that was placed every second day.
After ten days the cells were stained with 0.25% crystal violet.

DISCUSSION
The transcription factor NF-KB plays an important role in a variety of cells
through the initiation of transcription for genes involved in proliferation and
mitogenesis for numerous cell types. The results presented here indicate that NF-KB
also plays an integral part in the proliferation of glioblastomas, U87MG, Ul 18MG,
and breast carcinomas, T47D, MCF-7, MDA-MB-231 and to a lesser extent in
U373MG. Through chemical and genetic inhibition of NF-KB, I was able to decrease
the proliferation rates of these tumor cells. Unfortunately, inhibition of NF-KB
induced expression did not completely restore the normal phenotypes of these tumor
cells. Only at high concentrations of inhibitors was focus formation completely
eliminated and the tumor cells were never sensitive to contact inhibition as was seen
in the normal epithelial cells. The reduced focus formation in cells subjected to NF
KB inhibitory conditions was probably a direct result of reduced proliferation rates.
Overall, the glioblastoma lines, U87MG, U118MG tended to be most responsive to
NF-KB inhibition. The MDA-MB-231 breast carcinoma cell line was least effected
by NF-KB inhibition but this observation could be influenced by low transfection
efficiency within this line. The glioblastoma line, U373MG, consistently had lower
expression levels compared to the other tumor cell lines. It is interesting to note that
the U373MG line was the only tumor cell line not expressing the PDGF-B chain or�
receptor. Future studies should include elucidation of the mechanisms responsible
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for the increased NF-KB activity in these tumor cells. To definitively correlate PDGF
receptor signaling to NF-KB initiation of transcription within the tumor cells,
measurements of NF-KB activity need to be made in the presence of agonists and
antagonists of PDGF. Proteins such as Akt, Ras, Rae, Raf, MEK, PI3K, and MAPK
which are associated with PDGF and EGF nuclear signaling pathways could be ideal
targets for follow up inhibitory studies. Inhibiting the EGF and PDGF-a,� receptors
from phosphorylating cytoplasmic kinases within these cells could help establish the
specific relationship between the receptor, proliferation, and cellular transformation.
Differential expression studies between cells with NF-KB inhibition and without
could provide essential information on the genes activated by NF-KB in these tumor
lines. Expression studies with cell cycle proteins like cyclin D 1, which are known to
be dependent on NF-KB activation, could serve to give better evidence of cellular
transformation.

Because inhibition of NF-KB activity did not completely inhibit

proliferation of the cells, future experiments should examine other transcription
factors associated with growth and transformation of glioblastomas and breast
carcmomas.

In some research articles (Lim and Demo, 2000), the transcription

factors, AP-1 and SP-1, have been shown to be activated along with NF-KB.
Consideration has to be given to the AP-1 and SP-1 transcription factors because both
have similar roles in cell cycle regulation as NF-KB (Lim and Demo, 2000).
Therapeutic strategies associated with cancer treatment often involve prevention of
G 1 -to-S phase transitions in actively dividing cells (Rubin and Farber, 1997). NF-KB
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has been documented by many to be a major contributor of 0 1 -to-S phase transitions
in cells (Baeuerle and Baltimore, 1996, Guttridge et al., 1999). The conclusions
obtained in this investigation are similar to those gathered by other researchers on
NF-KB inhibition in cancerous cells (Abel-Mageed et al., 1998, Bargou et al., 1997,
Chin et al., 1999, Daley and Baltimore, 1988, Grimm and Baeurele, 1994, Marini et
al., 1990). Therefore, it came to no surprise an important regulator like NF-KB was

partly responsible for proliferation in these glioblastoma and breast carcinoma cell
lines.

Appendix A
Protocol Clearance From the Institutional
Biosafety Committee
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